3 US Penny Stocks With Market Caps Under $100M

As U.S. stocks experience fluctuations amid anticipation of key inflation data and interest rate decisions, investors are keenly observing market movements for potential opportunities. Penny stocks, a term that may seem outdated, continue to capture attention due to their affordability and growth potential, particularly when backed by strong financials. These smaller or newer companies can offer unique value propositions that larger firms might overlook, making them intriguing options for those seeking hidden gems in the market.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Financial Health Rating
Inter & Co (NasdaqGS:INTR)	$4.43	$1.94B	★★★★☆☆
BAB (OTCPK:BABB)	$0.86	$6.25M	★★★★★★
QuantaSing Group (NasdaqGM:QSG)	$3.08	$144.14M	★★★★★★
Imperial Petroleum (NasdaqCM:IMPP)	$2.89	$87.66M	★★★★★★
ZTEST Electronics (OTCPK:ZTST.F)	$0.24	$8.83M	★★★★★★
Permianville Royalty Trust (NYSE:PVL)	$1.49	$49.17M	★★★★★★
RLX Technology (NYSE:RLX)	$1.83	$2.33B	★★★★★★
Golden Growers Cooperative (OTCPK:GGRO.U)	$4.50	$69.71M	★★★★★★
CBAK Energy Technology (NasdaqCM:CBAT)	$0.9113	$81.96M	★★★★★☆
Zynerba Pharmaceuticals (NasdaqCM:ZYNE)	$1.30	$65.6M	★★★★★☆

Click here to see the full list of 705 stocks from our US Penny Stocks screener.

Let's dive into some prime choices out of the screener.

Cyclerion Therapeutics (NasdaqCM:CYCN)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Cyclerion Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for serious diseases, with a market cap of $9.11 million.

Operations: Cyclerion Therapeutics, Inc. does not have any reported revenue segments.

Market Cap: $9.11M

Cyclerion Therapeutics, Inc., with a market cap of US$9.11 million, is a pre-revenue biopharmaceutical company reporting minimal revenue of US$194K for the third quarter of 2024. The company remains unprofitable but has reduced losses over the past five years by 49.4% annually. Despite no long-term liabilities and short-term assets exceeding liabilities, Cyclerion faces less than a year of cash runway at current free cash flow levels. Shareholders have experienced dilution with shares outstanding increasing by 3.5%. The stock's high volatility reflects its speculative nature typical among penny stocks in this sector.

• Click here to discover the nuances of Cyclerion Therapeutics with our detailed analytical financial health report.
• Evaluate Cyclerion Therapeutics' historical performance by accessing our past performance report.

Harvard Bioscience (NasdaqGM:HBIO)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications globally, with a market cap of $98.56 million.

Operations: The company's revenue is generated from its Medical Products segment, which amounts to $97.73 million.

Market Cap: $98.56M

Harvard Bioscience, Inc., with a market cap of US$98.56 million, is experiencing financial challenges as it remains unprofitable and has seen increased losses over the past five years. The company's debt-to-equity ratio has improved from 71.3% to 58.3% over five years, yet its net debt level is high at 51.3%. Despite shareholder dilution and negative return on equity, Harvard Bioscience trades at a significant discount to its estimated fair value and maintains a cash runway exceeding three years due to positive free cash flow growth. Recent product innovations signal potential for future revenue streams amidst current sales declines.

• Click here and access our complete financial health analysis report to understand the dynamics of Harvard Bioscience.
• Understand Harvard Bioscience's earnings outlook by examining our growth report.

HilleVax (NasdaqGS:HLVX)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: HilleVax, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel vaccines in the United States, with a market cap of $96.95 million.

Operations: HilleVax, Inc. currently does not report any revenue segments as it is focused on the development and commercialization of innovative vaccines in the United States.

Market Cap: $96.95M

HilleVax, Inc., with a market cap of US$96.95 million, is pre-revenue and focused on developing vaccines. Despite being debt-free and having short-term assets of US$197.2 million that exceed its liabilities, the company remains unprofitable with increasing losses over five years. Recent earnings reports show a net loss reduction to US$25.82 million for Q3 2024 from US$31.82 million in the previous year, though losses have grown annually by 23.3%. The company has sufficient cash runway for more than a year but continues to dilute shareholders slightly and faces challenges in achieving profitability soon.

• Unlock comprehensive insights into our analysis of HilleVax stock in this financial health report.
• Gain insights into HilleVax's outlook and expected performance with our report on the company's earnings estimates.

Turning Ideas Into Actions

• Embark on your investment journey to our 705 US Penny Stocks selection here.
• Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.
• Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.

Seeking Other Investments?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com